Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 10 Jun 2024 12:09:19 +0200Fri, 31 May 2024 12:00:00 +0200Summary of opinion: Livmarli, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/livmarliSummary of opinion: Livmarli, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/livmarliFri, 31 May 2024 12:00:00 +0200Human medicineLivmarli : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5857-en_1.pdfLivmarli : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5857-en_1.pdfMon, 29 Jan 2024 12:35:00 +0100Human medicineHuman medicines European public assessment report (EPAR): Livmarli, Maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/livmarliHuman medicines European public assessment report (EPAR): Livmarli, Maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/livmarliMon, 29 Jan 2024 12:19:00 +0100Human medicine